title: Iodine-125 radioactive seed tissue implantation as a remedy treatment for recurrent cervical cancer.
abstract: OBJECTIVE
  This study was designed to discuss feasibility, short-term efficacy, and complications of iodine-125 radioactive seed tissue implantation for remedying recurrent cervical cancer.
  
  
  METHODS
  From June 2009 to December 2010, 17 patients with recurrent cervical cancer received radioactive seed implantation under computed tomography (CT) guidance. Matched peripheral dose was 145 Gy, while the number of implanted seeds was from 6 to 68 with a median of 20. Efficacy was determined based on the results of CT and 18 F-fluorodeoxyglucose positron emission tomography/CT.
  
  
  RESULTS
  Postoperative follow-ups were from 4 to 18 months with a median follow-up time of 9.5 months. Nine patients died during follow-up while remaining patients survived during the follow-up period. Evaluation of efficacy: six patients had a complete response, four patients had a partial response, and seven patients had progressive disease, clinical efficacy rate as 58% (10/17). No patients had complications of radiation injury. Rate of 6 months and 1-year survival period was 74.8% and 18.3%, respectively. Comparing to patients who responded ineffectively to radioactive seed implantation, patients who responded effectively to radioactive seed implantation had a longer survival period (median 7.2 vs. median 10.4), in which the difference was statistically significant (P = 0.038).
  
  
  CONCLUSIONS
  Iodine-125 radioactive seed tissue implantation is a feasible, effective, and safe treatment method for remedying or palliative treatment of recurrent cervical cancer. Patients who have recurrent cervical cancer and responded effectively to radioactive seed implantation will have a longer survival period.
authors.affiliation: Department of Oncology, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Han
authors.affiliation: Department of Oncology, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
authors.forename: Changlun
authors.initials: C
authors.lastname: Li
authors.affiliation: Department of Oncology, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
authors.forename: Junye
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Oncology, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
authors.forename: Xueqi
authors.initials: X
authors.lastname: He
authors.affiliation: Department of Oncology, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Oncology, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
authors.forename: Jundong
authors.initials: J
authors.lastname: Yang
authors.affiliation: Department of Oncology, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
authors.forename: Guofeng
authors.initials: G
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011183:Postoperative Complications; D016879:Salvage Therapy; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*
chemical_list: D007457:Iodine Radioisotopes